Citation, DOI, disclosures and article data
At the time the article was created Frank Gaillard had no recorded disclosures.View Frank Gaillard's current disclosures
At the time the article was last revised Frank Gaillard had the following disclosures:
- Radiopaedia Australia Pty Ltd and Radiopaedia Events Pty Ltd, Director, Founder and CEO (Radiopaedia) (ongoing)
- Biogen Australia Pty Ltd, Investigator-Initiated Research Grant for CAD software in multiple sclerosis: finished Oct 2021 (past)
These were assessed during peer review and were determined to not be relevant to the changes that were made.View Frank Gaillard's current disclosures
Synucleinopathies are a subgroup of neurodegenerative diseases, characterized by impairment of alpha-synuclein metabolism, resulting in abnormal intracellular deposits. They can further be divided into those with and those without the formation of Lewy bodies, although it should be noted that some overlap does exist 1,2,4:
- synucleinopathies with Lewy bodies
- synucleinopathies without Lewy bodies
α-synuclein is a neuronal protein of unclear function which accounts for approximately 1% of brain weight 1.
In addition to cerebral accumulation, α-synuclein also accumulates in the gastrointestinal tract resulting in symptoms 3.
Editor: more detail is required here pertaining to the genetic and biochemical underpinnings of these diseases, as well as any commonalities in presentation/demographics/ radiographic appearances.